A mobile application will be tested in elderly men and women that is randomized to an application (blind-app) that registers physical activity or an application (feedback-app) where participants in addition set goals for physical activity and gets feedback from the application when these goals are achieved. Participants are randomized in permuted blocks of 10 to the blind-app or feedback-app. The primary outcome is increased physical activity. Secondary outcomes include, cardiovascular disease, diabetes, death, dementia, cancer, falls and fractures.
In this randomized controlled study, it will be tested if a mobile application can increase physical activity and reduce the risk of later non-communicable disease. Participants include individuals that previously have been included in a health survey (Healthy aging initiative, NCT03312439), with a low registered physical activity. Low physical is defined according to WHOs definition, i.e. at least 150 minutes of physical activity per week. Individuals will diabetes will be investigated separately. Individuals will be excluded that cannot walk for exercise, or if they have diseases that severely affects the ability to exercise. We will also seek participants from the general population to be included with only two inclusion criteria; having a smart phone and at least 18 years of age. Participants the meet the inclusion criteria will be randomized to an application that only registers physical activity (blind-app) or an application where the participants will set appropriate goals for physical activity and get proper feedback from the app when these goals are reached (feedback-app). Both groups will have individualized information about proper physical activity. Randomization will be made using sealed envelopes in permuted blocks of 10. Randomization will be stratified on year of birth and sex. The primary outcome will be increased physical activity after 6 months. Secondary outcomes include cardiovascular disease, death, dementia, falls and fractures, diabetes, and improved glucose control in those that already have diabetes. Secondary outcomes also include changes in cardiovascular risk factors, such as blood pressure, blood lipids and obesity. Interaction analysis will be performed to investigate if the effects are different in men and women, based on baseline physical activity and based on age. Based on the results from the previous health survey the individuals have participated in, a power analyses has been conducted. The participants physical activity were registered using accelerometers. The mean steps taken per week was 48000 with a standard deviation of 22000 steps. With assumption that the feedback-app will increase physical activity by at least 15%, 164 individuals would be needed in each group with an alpha level of 0.05 and a power of 80%. For secondary outcome of cardiovascular disease or death, estimates were based on incidence of these outcomes in 3617 individuals that participated in the health survey. During a mean follow up time of 928 days, 221 participants was diagnosed with cardiovascular disease or died during follow up, and 128 were diagnosed with cardiovascular disease. If assuming that the mobil-application will result in 15% lower risk of these two outcomes in those randomized to the feedback-app, 597 and 1371 individuals would be needed in each group, respectively, with the same follow up time. The effects during follow up will be monitored each year of follow up through patient registers. Follow up time is scheduled to a maximum of 2 years. We estimate that we then would need 895 and 2156 individuals in each group due to the shorter follow up time compared to in the example above.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
4,000
The active group will be given the feedback app and the control group the blind app
Increased physical activity as measured by the mobile application in steps per day
Increased physical activity in steps per day during the intervention period.
Time frame: 3 years (anticipated)
Incidence of myocardial infarction
Diagnoses of myocardial infarction will be tracked using national registers.
Time frame: 3 years
Incidence of diagnosed diabetes
Diabetes diagnoses or start of treatment for diabetes will be tracked using national registers.
Time frame: 3 years
Incidence of diagnosed fractures
Diagnosed fractures will be tracked using national registers.
Time frame: 3 years
Incidence of diagnosed dementia
Diagnosed dementia or start of treatment using dementia drugs will be tracked using national registers.
Time frame: 3 years
Number of participants with high blood pressure
Systolic and diastolic blood pressure will be assessed at baseline and later using a sphygmomanometer.
Time frame: 1 year (anticipated)
Number of participants with high blood lipids
Blood lipids (cholesterol, LDL-cholesterol, and triglycerides) will be analyzed at baseline and after 6 and 12 months at the department of chemistry.
Time frame: 1 year (anticipated)
Number of participants with high blood glucose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Blood glucose will be analysed at the departement of clinical chemistry at baseline and follow up.
Time frame: 1 year (anticipated)
Grade of obesity
Obesity will be assessed using a non-elastic measurement tape at the waist
Time frame: 1 year (anticipated)
Body weight
Body weight in kilogram measured by a digital scale.
Time frame: 1 year (anticipated)
Incidence of stroke
Diagnoses of stroke will be tracked using national registers.
Time frame: 3 years
Incidence of angina pectoris
Diagnoses of angina pectoris will be tracked using national registers.
Time frame: 3 years
Incident mortality
Death during follow up will be tracked using national registers.
Time frame: 3 years
Number of participants with high glycated hemoglobin
Glycated hemoglobin will be measured at baseline and follow up at the Department of clinical chemistry
Time frame: 1 year (anticipated)